HIGH HEART RATE AS A POTENTIAL RISK FACTOR FOR DEVELOPMENT OF CARDIOVASCULAR DISEASES IN WOMEN WITH RHEUMATOID ARTHRITIS

Aim. To study relationship between heart rate (HR) and traditional risk factors for cardiovascular diseases (TRF for CVD), subclinical structural and functional changes in the heart and vessels, as well as the activity and severity of rheumatoid inflammation in women with rheumatoid arthritis (RA). Material and methods. A total of 291 female patients less than 60 years of age with a definite diagnosis of RA were examined. The control group consisted of 125 women without rheumatic diseases. Aside from clinical symptoms, activity and severity level of RA, the presence of main TRF for CVD were assessed, 24 h Holter ECG monitoring (24-h ECG), duplex scanning of common carotid arteries, transthoracic echocardiography were performed and the serum levels of inflammatory markers were determined.  Results. RA patients compared with the control group women had higher values of minimum (52.3±0.4 vs 47.5±0.4; p<0.001) and mean (78.5±0.5 vs 75.5±0.5; p<0.001) HR according to 24-h ECG, after adjustment for main TRF for CVD (age, arterial hypertension, menopause, levels of total cholesterol, triglycerides, high density lipoprotein cholesterol). Accelerated HR in RA directly correlated with an increased joint functional disability index - HAQ, RA severity index, the level of inflammatory markers and administration of leflunomide after adjustment for age (р<0.05). Patients with HR≥86 beats per minute compared with RA patients with values of HR≤71 beats per min had lower total cholesterol (5.84±0.13 vs 5.11±0.17; p=0.001) and low density lipoprotein cholesterol levels (4.06±0.13 vs 3.28±0.18; p=0.001), longer duration, higher activity (Visual Analog Pain Scale, DAS28, extra-articular manifestations of RA, concentration of proinflammatory markers) and severity level of RA (severity index, HAQ, radiological stage III/IV), as well as  higher percentage of left ventricular diastolic dysfunction (LVDD) after adjustment for age. Conclusion. According to 24-h ECG, an increase in mean HR values in women with RA is associated with activity , severity of rheumatoid inflammation and LVDD. Prospective studies are needed to determine the role of accelerated HR as a risk factor for development of CVD and the feasibility of preventive measures creation aimed to lower HR to prevent cardiovascular events in RA.

1. Meune C., Touze E., Trinqurte L., Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009;48:1309-13.

2. Meune C., Touzé E., Trinquart L., Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010;103:253-61.

3. Crowson C.S., Gabriel S.E. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 2011;70(5):719-21.

4. Leuven S.I., Franssen R., Kastelein J.J. et al. Systemic inflammation as a risk factor for atherothrombo-sis. Rheumatology 2008;47:3-7.

5. Koopman F.A., Stoof S.P., Straub R.H. et al. Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis. Mol Med 2011;17(9-10):937-48.

6. Novikova DS, Popkova TV, Markelova EI et al. Clinical significance of the assessment of cardiac rhythm variability in patients with rheumatoid arthritis. Klin Med (Mosk) 2009;87(1):27-32. Russian (Новикова Д.С., Попкова Т.В., Маркелова Е.И. и соавт. Клиническое значение оценки вариабельности ритма сердца у больных ревматоидным артритом. Клиническая медицина 2009;1:27–32).

7. Anichkov D.A., Platonova A.A. Clinical significance of heart rate variability indexes derived from 5-minute and 24-hour ECG recordings in patients with rheumatoid arthritis. Rational Pharmacother. Card. 2009;(1):77-82. Russian (Аничков Д.А., Платонова А.А. Клиническое значение показателей вариабельности сердечного ритма (по данным 5-минутных и 24-часовых записей ЭКГ) у больных ревматоидным артритом. РФК 2009;(1):77–82).

8. Cook S., Togni M., Schaub M. et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006;27:2387–93.

9. Goldberg R.J., Larson M., Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study. Arch Intern Med 1996;156:505-10.

10. Schwartz R.J. The neural control of heart rate and risk stratification after myocardial infarction. Eur Heart J 1999;1(Suppl H):H33-H43.

11. Dyer A.R., Persky V., Stamler J. et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112:736-49.

12. Kannel W.B., Kannel C., Paffenbarger R.S. et al. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987;113:1489-94.

13. Wannamethee G., Shaper A.G., Macfarlane P.W. et al. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995;91:1749-56.

14. Gillum R., Makus D., Feldman J. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J 1991;121:172-7.

15. Aronow W., Ahn C., Mercando A., Epsteim S. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996;78:1175-6.

16. Sajadieh A., Nielsen O., Rusmussen V. et al. Increased heart rate and reduced heart rate variability are associated with subclinical inflammation in middle-age and elderly subjects with no apparent heart diseases. Eur Heart J 2004;25:363–70.

17. Arnett F.C., Edworthy S.M., Bloch D.A. The ARA 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

18. Rheumatoid arthritis. Q: Nasonov EL, editor. Clinical recommendations. Rheumatology. Moscow: GEOTAR-Media; 2010: 25-72. Russian (Rheumatoid arthritis. В: Насонов Е.Л., редактор. Клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа; 2010: 25-72).

19. De BackerG., Ambrosioni E., Borch-Johnsen K. et al. Third Joint Force of European and other Societies on Cardiovascular Disease and Prevention in Clinical Practice. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis 2003;171:145-55.

20. Haward G., Sharrett A.R., Heiss G. et al. Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke 1993;24:1297-1304.

21. National guidelines for diagnosis and treatment of hypertension (4th revision). Sistemye Gipertenzii 2010; (3):5-26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26).

22. National guidelines for diagnosis and treatment of chronic heart failure. Serdechnaya Nedostatochnost' 2010;11(1): 1-45. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности. Сердечная недостаточность 2010;11(1): 1-45).

23. Gerasimov A.N. Meditsinskaya statistika. Moscow: Meditsinskoe informatsionnoe agentstvo; 2007. Russian (Герасимов А.Н. Медицинская статистика. М.: Медицинское информационное агентство; 2007).

24. Cramer H. Mathematical Methods of Statistics (PMS-9). Princeton: Princeton University Press; 1999.

25. Shal'nova SA, Deev AD, Oganov RG et al. Pulse rate and cardiovascular mortality of men and women in Russia. Results of epidemiological studies. Kardiologiia 2005;45(10):45-50. Russian (Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005;(10):45−50).

26. Copie X., Hnatkova K., Staunton A. et al. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. J Am Coll Cardiol 1996; 27:270-6.

27. Palatini P., Julius S. Heart rate and cardiovascular risk. J Hypertens 1997;15:3−17.

28. Goodson N.J., Symmons D.P., Scott D.G., Bunn D., Lunt M., Silman A.J. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow up study of a primary care-based inception cohort. Arthritis Rheum 2005; 52:2293-9.

29. Poole C.D., Conway P., Currie C.J. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009; 48:78-82.

30. Jacobsson L.T., Turesson C., Hanson R.L. et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 2001; 44:1170-6.

31. Wållberg-Jonsson S., Johansson H., Ohman M.L., Rantapää-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26:2562-71.

32. Rho Y.H., Chung C.P., Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009;15;61:1580-5.

33. Goodson N.J., Wiles N.J., Lunt M., Barrett E.M., Silman A.J., Symmons D.P. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthritis Rheum 2002;46:2010-9.

34. López-Longo F.J., Oliver-Miñarro D., de la Torre I. et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:419-24.

35. Naranjo A., Sokka T., Descalzo M.A. et al.; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr Res Ther 2008;10(2):R30.

36. Solomon D.H., Avorn J., Katz J.N. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthr Rheum 2006;54:3790–8.

37. Rozman B., Praprotnik S., Logar D. et al. Leflunomide and hypertension. Ann Rheum Dis 2002;61:567–9.

38. Myasoedova E., Crowson C.S., Kremers H.M.et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70(3):482–7.